NewsOK Local Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Akebia Therapeutics (NQ: AKBA)
4.260 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:15 PM EDT, Oct 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 4.260
Bid (Size) 3.490 (20)
Ask (Size) 4.900 (2)
Prev. Close 4.260
Today's Range 4.260 - 4.260
52wk Range 3.500 - 10.45
Shares Outstanding 56,913,886
Dividend Yield N/A
Performance
YTD
-26.55%
-26.55%
1 Month
-3.62%
-3.62%
3 Month
+6.50%
+6.50%
6 Month
-36.13%
-36.13%
1 Year
-48.67%
-48.67%
Top News
More News
Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement f
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a fully integrated biopharmaceutical company focused on bettering the lives of people impacted by kidney disease, today filed a complaint in federal district... Read More
from Business Wire News Releases
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired... Read More
from Business Wire News Releases
More News
Read More
Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
from Business Wire News Releases
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from Business Wire News Releases
Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
from Business Wire News Releases
Akebia Therapeutics to Participate in Upcoming Investor Conferences
from Business Wire News Releases
Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights
from Business Wire News Releases
Akebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par Pharmaceutical
from Business Wire News Releases
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from Business Wire News Releases
Analysts Anticipate IWV Will Reach $192
category ETFs
from ETF Channel
Akebia Therapeutics to Report Second Quarter 2019 Financial Results
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.